Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture
Figure 1
Changes in best-corrected visual acuity (BCVA) after intravitreal bevacizumab. BCVA improved at 1 month from 0.90 to 0.76 (logarithm of the minimum angle of resolution), a difference that was statistically significant (), this level of BCVA was maintained throughout 3-, 6-, 12-, and 24-months. CI: confidence interval (Reprinted with permission from [13]).
